Why Signify Has The Potential To Add Significant Value To CVS’s Stock

Naysayers may be quick to argue that CVS is still paying too much for a company expecting to produce less than $250 million in adjusted EBITDA in 2022. But there are good reasons why SGFY commanded such a price tag and why it was also reportedly being pursued by other heavy hitters like [...]